Introduction
Urinary tract infection (UTI) is one of the most common medical problems in the general population 1 . Among kidney transplant recipients, UTIs occur at an alarmingly high rate 2 . Bacterial UTI affects at least 20% of kidney transplant recipients in the first year after transplantation 3 , and at least 50% in the first three years after transplantion 4 . In addition, complications due to viral infection occur often. An estimated 5-8% of kidney transplant recipients suffer nephropathy from BK polyomavirus infection in the first three years after transplantation 5, 6 . Other viral infections in kidney transplant recipients include adenovirus, JC polyomavirus, cytomegalovirus (CMV), and parvovirus. The current gold standard for diagnosis of bacterial UTI is in vitro urine culture 7 . Although improved culture methods are being investigated 8 , bacterial culture is limited to detection of relatively few cultivable organisms. A recent study reports that almost all women with symptoms of UTI but a negative culture still have an infection 9 . In addition, bacterial culture is unable to inform about commensal microbiota, viral infections, or about bacterial growth dynamics. Last, urinalysis is often required in conjunction with culture to make treatment decisions.
A large number of small fragments of cell-free DNA (cfDNA) are present in plasma and urine [10] [11] [12] . These molecules are the debris of cell death across the body and offer opportunities for precision diagnostics based on 'omics principles, with applications in a wide range of medical settings, including pregnancy, cancer and solid-organ transplantation [12] [13] [14] [15] . Here, we have investigated the utility of urinary cfDNA to comprehensively monitor host and pathogen dynamics that arise in the scope of viral and bacterial infections of the urinary tract. We used unbiased sequencing to assay cfDNA isolated from 115 urine samples collected from a cohort of 67 kidney transplant recipients, including patients diagnosed with bacterial UTIs and BK polyomavirus nephropathy. We implemented a single-stranded DNA (ssDNA) sequencing library preparation, optimized for the analysis of ultrashort DNA fragments (average length less than 100 bp), and were able to perform robust analyses of ultrashort cfDNA isolated from just one milliliter of urine supernatant 16, 17 . We find that urinary cfDNA detects clinically identified uropathogens, while also uncovering co-infections and frequent viral and bacterial infections that remain undiagnosed in conventional diagnostic workups.
We further investigated cfDNA analysis methodologies that go beyond mere identification of microbial sequences and provide a deeper understanding of ongoing infections. First, we show that the pattern of cfDNA sequencing read coverage across bacterial genomes is highly non-uniform, with an overrepresentation of sequences at the origin of replication. A similar pattern has previously been observed in whole genome sequencing of gut microbiome communities, and the disproportionate genome coverage was shown to reflect the bacterial growth rate, where an overrepresentation of genomic coverage at the replication origin signals faster growth 18 . Here, we show that quantifying bacterial growth rates from urinary cfDNA can be used to inform diagnosis of UTI. Second, we mined cfDNA for antimicrobial resistance (AR) genes and show that antimicrobial resistome profiles can be used to evaluate the susceptibility to antibacterial therapy. Last, we show that cfDNA informs about the host response to infection on both a cellular and tissue level. Recent reports have demonstrated that cfDNA in plasma comprises the footprints of DNAbinding proteins and nucleosomes. We show, for the first time, that nucleosome structures within transcription regulatory elements are preserved in urinary cfDNA, as was previously described for plasma cfDNA 19 . We find that the occupancy of nucleosomes in gene regions flanking the transcription start site is notably reduced for transcribed genes, consistent with known chromatin alterations in gene promoters during transcription, thus providing a measure of gene expression. We furthermore find that the relative proportion of kidney donor specific cfDNA indicates graft tissue injury in the scope of viral infection and host immune cell activation in the scope of bacterial infection. Finally, we report that the graft is the predominant source of mitochondrial cfDNA in the urine of kidney transplant recipients with BK polyomavirus nephropathy.
Collectively, this study supports the utility of unbiased sequencing of urinary cfDNA as a comprehensive tool for monitoring patient health and discovering novel interactions between pathogens and the host.
Results

Biophysical properties of urinary cell-free DNA
Urinary cfDNA is comprised of chromosomal, mitochondrial, and microbial cfDNA released from host cells and microbes in the urinary tract and of plasma-derived cfDNA that passes from the blood circulation into urine 20 . Urine can be collected non-invasively in large volumes, and therefore represents an attractive target for diagnostic assays. Compared to plasma DNA, relatively few studies have examined the properties and diagnostic potential of urinary cfDNA. The urinary environment degrades nucleic acids more rapidly than plasma resulting in fewer DNA fragments that are far shorter 21 . Consequently, sequence analyses of urinary cfDNA have to date required relatively large (> 10 ml) volumes of urine 22, 23 . Here, we applied a single-stranded library preparation technique that employs ssDNA adapters and bead ligation to create diverse sequencing libraries that capture short, highly degraded cfDNA 16, 17 (Fig. 1A) . We find that singlestranded library preparation enables robust sequence analyses of urinary cfDNA from just one milliliter of cell-free urine supernatant. The sequencing libraries comprised on average 4.07 billion unique molecules. We assayed 115 urine samples collected from kidney transplant recipients, including subjects diagnosed with bacterial UTI and BK polyomavirus nephropathy (overview of collection dates and categories depicted in Fig.  1B , see Methods for a detailed description of the study cohort). We obtained 38.2 +/-12.1 million paired-end reads per sample, yielding a per-base human genome coverage of 0.42x +/-0.14x. Many fragments aligned to microbiota, for example, for patients diagnosed with bacterial UTI, bacterial cfDNA accounted for up to 34.65% of the raw sequencing reads and in cases of BK polyomavirus nephropathy, polyomavirus cfDNA accounted for up to 10.27% of raw sequencing reads. To account for technical variability and sources of environmental contamination during extraction and library preparation, a known-template control sample was included in every sample batch and sequenced (see Methods).
We analyzed the fragment length profiles of urinary cfDNA at single nucleotide resolution using paired-end read mapping 10 . This analysis confirmed previous observations of the highly fragmented nature of urinary cfDNA compared to plasma cfDNA 22 (Fig. 1C) . We observed a 10.4 bp periodicity in the fragment length profile for chromosomal cfDNA in the urine (Fourier analysis, Fig. 1C , inset), consistent with the periodicity of DNA-histone contacts in nucleosomes. Polyomavirus is known to hijack histones of infected host cells, and to form minichromosomes after infection 24 . The fragment length profiles of BK polyomavirus cfDNA in urine reflect this pathobiology, and indicate a predominant nucleosomal origin of polyomavirus cfDNA (Fig. 1C) . A similar nucleosomal footprint is not observed for bacterial and mitochondrial cfDNA, and cfDNA arising from parvovirus, which is expected given the non-nucleosomal compaction of the genomes that contribute these cfDNA types (Fig. 1D ). These data demonstrate that analyses of the structure of cfDNA can be used to learn about the pathobiology of uropathogens.
Infectome screening
We assessed the presence of cfDNA from bacterial and viral pathogens reported in clinical diagnostic workups. Here, we used previously described bioinformatics approaches to quantify non-human cfDNA sequences in the datasets 25 . Briefly, human sequences were identified by alignment of the sequences to the human reference and removed. Remaining sequences were BLASTed against a custom database of microbial reference genomes. We estimated the relative genomic representation of different species using GRAMMy 26 . To directly compare the measured microbial abundance across samples and species, we computed the representation of microbial genome copies relative to the representation of the human genome in the datasets, and expressed this quantity as RGE, relative genome equivalents.
We detected an extremely high load of BK polyomavirus cfDNA in all 24 samples collected from 22 patients with BK polyomavirus nephropathy (BKVN) per needle biopsy (mean 1.5 +/-1.1 x10 5 RGE, Fig. 2A ), but not in 10 patients that were BKVN negative per needle biopsy (mean 0.17 RGE). This high load of BK derived DNA is consistent with the pathobiology of BKVN. The BK cfDNA abundance (RGE) correlated with a urine cell pellet BKV VP1 mRNA copy measurement that has been validated as a noninvasive diagnostic biomarker for BKVN 27, 28 (Spearman: ρ = 0.73, p = 1.0 x10 -6 ).
We quantified bacterial urinary cfDNA in 27 urine samples from 17 patients who had a corresponding positive conventional bacterial culture on the same day. For 26 out of 27 clinically positive samples (based on conventional bacterial culture), unbiased sequencing of urinary cfDNA detected the clinically reported uropathogen (Fig. 2B) , with 25 of the 27 pathogens identified by culture being in the top 10 abundant organisms identified by cfDNA. For a single sample, urinary cfDNA did not detect the uropathogen reported in culture (Raoultella was not detected in the corresponding diagnosed sample, see detailed discussion of this discordant readout and its clinical implications in methods). In another sample, we confirmed co-detection of Enterococcus and Staphylococcus, matching the only clinically reported polymicrobial infection in this study -a co-infection of Enterococcus faecalis and coagulase-negative Staphylococcus. To test the performance of urinary cfDNA to identify specific genera, we compared the relative abundance measured for patients diagnosed with a specific agent (n = 27) against the relative abundance measured for 40 negative urine cultures (defined as < 10,000 CFU/mL) from 29 patients (Fig. 2C ). We find agreement between urinary cfDNA and clinical testing for Enterococcus (n=9, AUC 95% CI 0.911-1.000), E. coli (n=9, AUC 95% CI 0.904-1.000), Klebsiella (n=3, AUC 1.000), and Pseudomonas (n=3, AUC 1.000).
In just over half (59%, 16 of the 27 UTI cases) of examined samples, we found that the uropathogen reported by culture was the most prevalent pathogen in the sample (Fig.  2B ). Whereas reports of bacterial culture are skewed towards species that are responsive to culture, cfDNA sequence analyses are sensitive to the full spectrum of uropathogens.
Cell-free DNA reveals frequent undiagnosed viral infections
We next screened for the occurrence of viral uropathogens, including those not tested for in the clinical protocol currently in place in our transplant program. Approximately twothirds of samples (n = 78) had detectable levels of clinically relevant viruses in the whole cohort of 115 urine specimens. Figure 2D highlights the occurrence of different viruses across specific patient groups and reveals the frequent occurrence of infections with JC polyomavirus, Merkel cell polyomavirus, several herpesviruses (Epstein-Barr virus, cytomegalovirus, human herpesvirus 6A and 6B, human herpesvirus 1) and various known oncoviruses in this cohort. In addition, we detected parvovirus in twelve samples, with a very high abundance in one sample (1.715 x10 4 RGE). Several patients were simultaneously infected with different polyomavirus species (Merkel cell, JC polyomavirus, or BK polyomavirus). These data illustrate the disconnect that exists between the frequency of current clinical infection testing and the incidence of viral pathogens in this cohort of transplant patients.
Quantifying bacterial growth rates
Conventional metagenomic sequencing can provide a snapshot of the microbiome, yet does not inform about microbial life cycles or growth dynamics. In a recent study, Korem et al. reported that the pattern of metagenomic sequencing read coverage across a microbial genome can be used to quantify microbial genome replication rates for microbes in complex communities 18 . Here, we tested whether this concept can be used to estimate bacterial growth dynamics from measurements of cell-free DNA. Figure 3A shows the urinary cfDNA sequence coverage for four bacterial species, E. coli, K. pneumoniae, G. vaginalis and P. acnes. For two patients diagnosed with E. coli and K. pneumoniae UTI (Fig. 3A) , the E. coli and K. pneumoniae genome coverage was highly non-uniform, with an overrepresentation of sequences at the origin of replication and an underrepresentation of sequences at the replication terminus. The shape of the E. coli and K. pneumoniae genome coverage is a result of bi-directional replication from a single origin of replication. The skew in genome coverage reflects the bacterial growth rate, where a stronger skew signals faster growth 29 . The genome coverage of a typically commensal bacterial species, Gardnerella vaginalis, exhibited non-uniform genome coverage (Fig. 3A, G. vaginalis) , similar to the above uropathogens but less pronounced. Propionibacterium acnes has been recognized as a common skin and lab contaminant 30 . The genome coverage for P. acnes, was highly uniform, indicative of slow or no growth (aggregate across 81 samples, Fig. 3A ).
We asked whether this measure of bacterial growth can be used to inform UTI diagnosis. We calculated an index of replication based on the shape of the sequencing coverage using methods described previously 29 . For 81 samples, we used BLAST to identify abundant bacterial strains and then re-aligned all sequences with BWA to a curated list of bacterial species. Samples for which the genome coverage was too sparse or too inhomogeneous were excluded from this analysis (see Methods). Figure 3B compares the index of replication for bacteria in samples from patients diagnosed with UTI, to bacteria in samples from patients with negative cultures and samples collected from patients before and after UTI diagnosis. Species categorized in the UTI group had markedly greater growth rates, than those in the no UTI and pre-/post-UTI groups (twotailed Wilcox rank sum test, p = 0.034). A single-snapshot measurement of bacterial growth from cfDNA may enable identification of virulent microbial strains and evaluation of the response to anti-bacterial drug treatments.
Antimicrobial resistome profiling
For 25 of 27 samples collected from patients with clinically confirmed UTIs, we determined the relative abundance of genes conferring resistance to several classes of antibiotics. Here, we aligned non-human sequences against known antibacterial resistance genes and mutations using blastp again the Comprehensive Antibiotic Resistance Database (CARD) 31 (see Methods). AR gene sequences were aggregated and called against a non-redundant CARD reference that indicates the drug resistance conferred by the given gene.
We compared clinical profiles of antimicrobial susceptibility testing (see Methods) to the resistance profiles determined by sequencing. For most samples, there was a high diversity in alignments with highly abundant resistance classes including resistance to macrolides, aminoglycosides, and beta-lactams (Fig. 4) . We studied vancomycinresistant Enterococcus (VRE) infections, which often lead to complications after transplantation, in depth. For all samples diagnosed with Enterococcus UTI (9 samples from 6 patients), resistance to vancomycin was assessed via measurement of minimum inhibitory concentration or bioMérieux Etest. We detected fragments of genes conferring resistance to the glycopeptide antibiotic class, of which vancomycin is a member, for all VRE positive samples (n=3). Moreover, for samples with Enterococcus UTI that were identified as vancomycin susceptible (n=6), we did not detect glycopeptide class resistance. When expanding to all samples, we identified vancomycin resistance in one additional sample from a patient who had developed VRE UTI prior to the collection of the urine sample but was untreated (see below). These data indicate significant potential to predict antimicrobial susceptibility from measurements of urinary cfDNA.
Host response to infection
We next examined the host response to viral and bacterial infections. Recent work has identified transplant donor specific cfDNA in plasma as a marker of graft injury in heart, lung, liver and kidney transplantation 14, 25, 32, 33 . Here, we quantified donor specific cfDNA in urine for sex-mismatched donor recipient pairs by counting Y chromosome derived cfDNA (Fig. 5A, Methods) . We observed elevated levels of donor cfDNA for samples from patients diagnosed with BKVN (mean proportion of donor DNA 65.6%, n=13) compared to samples from patients who had normal protocol biopsies without diagnosis of BKVN (mean 51.4%, n=4) and samples from patients who did not develop a clinical UTI in the first 3 months of transplantation (mean 23.4%, n=12, samples collected within 5 days after transplant excluded). The release of donor DNA reflects severe cellular and tissue injury in the graft, a hallmark of BKVN. In contrast to patients diagnosed with polyomavirus infection, patients diagnosed with bacterial UTI had lower proportions of donor DNA as compared to stable individuals. This is likely explained by an elevated number of recipient immune cells in the urinary tract following immune activation. Indeed, comparison to clinical urinalysis indicates that the donor fraction decreases with white blood cell count (WBC) per high power field, HPF (400x magnification, inset Fig. 5A , Spearman: ρ = -0.424, p = 0.01). Furthermore, clinical cases of pyuria -defined as greater than ten WBC per HPF -had a lower donor fraction than those without (two-tailed Wilcox rank sum test, p = 0.01). In addition, we found that the level of donor DNA in the first few days after transplant was elevated, consistent with early graft injury, and in line with earlier observations in heart and lung transplantation 25, 34 . We tracked the relative and absolute abundance of donor specific urinary cfDNA in the first few days after transplantation for a small subset of patients. The initial elevated level of donor DNA quickly decayed to a lower baseline level (Fig. 5B ), in line with previous observations in heart and lung transplantation 14, 35 .
Two recent studies have demonstrated that the structure of chromatin in gene promoters is conserved within circulating cfDNA in plasma 19, 36 . Ulz et al. employed whole-genome sequencing of plasma DNA to show that nucleosomal occupancy at transcription start sites (TSSs) results in different read depth coverage patterns for expressed and silent genes 19 . Here, we have found for the first time that the footprints of nucleosomes in gene promoters and transcriptional regulatory elements are conserved within urinary cfDNA (Fig. 5C , aggregation and normalization across all samples), and that the extent of nucleosomal protection is proportional to gene expression. Measurements of nucleosomal depletion can serve as a proxy for gene expression, and may be used to investigate host-pathogen interactions in the scope of urinary tract infection in more detail.
Mitochondrial DNA (mtDNA) in the urine was recently identified as a possible biomarker for hypertensive kidney damage 37 . Recent data furthermore indicate a role for extracellular mitochondrial DNA as a powerful damage-associated molecular pattern (DAMP) -elevated levels of mtDNA in plasma have been reported in trauma, sepsis and cancer and recent studies have identified mitochondrial DNA released into the circulation by necrotic cells 38 . For a small subset of patients diagnosed with BKVN (8 samples from 7 patients), we quantified donor and recipient specific mtDNA in urine, using an approach we have previously described 17 . We found that the graft is the predominant source of mitochondrial urinary cfDNA in seven of the eight samples (two-tailed Student t-test, p << 10 -6 ; see Methods). Molecular techniques to track DAMPs in urine released in the scope of kidney graft injury may provide a non-invasive window into the potential role of these molecules in the pathogenesis of immune-related complications.
Finally, to illustrate the utility of urinary cfDNA monitoring, we conclude with a case study. A kidney transplant recipient clinically presented with an E. coli infection on posttransplant day 13 and was placed on a two-week course of ertapenem/meropenem, starting post-operative day 15. On day 20 (cfDNA available), the patient had a urine culture positive for VRE infection while on ertapenem/meropenem. On day 27 (cfDNA available), a urine culture was negative for both E. coli and VRE. Urinary cfDNA profiling revealed a high abundance of Enterococcus cfDNA at day 20 (2.473 RGE), as well as the presence of glycopeptide class resistance (GCR) genes. A low donor fraction was measured (11.8%), indicative of immune activation. At day 27, the presence of Enterococcus cfDNA (1.028 RGE) and GCR genes diminished while the fraction of donor cfDNA nearly doubled (D = 21.2%), indicating successful treatment. However, by day 31, four days after the antibiotic treatment concluded, the abundance of Enterococcus cfDNA (49.5 RGE) and GCR genes had increased, and the donor fraction decreased (D = 10.3%), indicating relapse. Conventional culture was not performed at that time. The patient in question later developed E. coli UTIs (post-operative day 232, and 337) and VRE UTIs (post-operative day 260 and 337). This case illustrates how the different layers of information acquired from cfDNA -microbiome composition, recipient DNA, and ARG identification -might have predicted the recurrence of infection in this patient.
Discussion
We have presented a strategy to comprehensively identify and assess infections of the urinary tract based on profiling of urinary cfDNA and 'omics analysis principles. We show that different layers of clinical information are accessible from a single assay that are either inaccessible using current diagnostic protocols, or require parallel implementation of a multitude of different tests. In nearly all samples with clinically reported viral or bacterial infection of the urinary tract, cfDNA identified the causative agent of infection. cfDNA furthermore revealed the frequent occurrence of both viral and bacterial (co-)infections that remain unidentified in current clinical practice. In many samples, including samples from patients regarded as clinically stable, we detected viral infections that may be clinically relevant but not routinely assayed in the screening protocol at our institution. The assay we present therefore has the potential to become a valuable tool for the monitoring of bacterial and/or viral infections in transplant cohorts, and ascertain their potential impact on allograft health.
Cell-free DNA in the blood circulation is, to a large extent, cleared from the blood via the kidneys. Analyses of urinary cfDNA can therefore reveal infections that occur throughout the body, and are not limited to the detection of infections of the urinary tract. Blood collection requires a minimally invasive procedure, whereas urine can be collected entirely noninvasively, repeatedly, and without need for clinical visitation. In this light, urine may prove an ideal specimen type for whole-body infection analysis based on unbiased sequencing of cfDNA.
Beyond measurements of the abundance of different components of the microbiome, urinary cfDNA provides information about uropathogen phenotypes. We show, for the first time, that analysis of the structure of microbial genomes from cfDNA allows estimating bacterial growth rates, thereby providing dynamic information from a single snapshot. We compared the bacterial growth rates in samples with clinically-diagnosed UTI to those with no confirmed UTI and we observed higher growth rates for both clinically-diagnosed and co-infecting bacteria in patients with infection. The bacterial growth rate measurement may have the potential to measure the effect of antibiotic treatment from a single snapshot.
We further show that metagenomic analysis of urinary cfDNA can be used to evaluate the susceptibility to antibiotics. We compared sequencing data to a curated database of genes conferring antibacterial resistance, and we found a good agreement between the alignments to AR genes and reports of drug resistance determined via minimum inhibitory concentration measurements. cfDNA resistome profiling may have an added potential over conventional culture as cultures report on the susceptibility testing of one or few cultured colonies. cfDNA profiling can capture AR gene fragments from the entire bacterial population which may be particularly important since cfDNA profiling reveals frequent co-infections within the UTI group. Linking determinants of bacterial resistance to specific strains is challenging for complex infections. UTI offers a good test ground for such analyses, given the low complexity and abundance of normal flora that challenge AR analyses.
More than 15,000 patients receive lifesaving kidney transplants in the US each year 39 . Viral and bacterial infections of the urinary tract occur frequently in this patient group and often lead to serious complications, including graft loss and death. In the general population, UTI is one of the most frequent medical problems that patients present with in medical offices 40 . Unbiased sequencing of cfDNA offers a comprehensive window into the pathobiology of infections of the urinary tract and can be a valuable future diagnostic tool to monitor and diagnose bacterial and viral infections in kidney transplantation as well as in the general population. The assay we have presented can be robustly implemented on low volumes of urine and will benefit from continued technical advances in DNA sequencing that will reduce cost and assay turnaround time in the years to come.
Methods
Study cohort and sample collection. 115 urine samples were collected from kidney transplant recipients who received their clinical care at New York Presbyterian HospitalWeill Cornell Medical Center. We assayed urine samples from a total of 67 patients. We included 21 subjects who developed bacterial UTIs diagnosed within the first 3 months of transplantation and 14 subjects who never developed urinary tract infections within the first 3 months of transplantation. For the 21 subjects who developed UTIs, we assayed 27 urine samples from 17 subjects who had corresponding, same day positive urine cultures (UTI Group); we assayed 15 urine samples from 15 subjects, collected at least 2 to 25 days (median 7 days) prior to development of the positive urine cultures (Pre-UTI Group), and we assayed 10 urine samples from 8 subjects, collected at least 3 to 31 days (median 12 days) after development of the positive urine cultures (Post-UTI Group) (7 of the 8 subjects were treated with antibiotics). We assayed a total of 29 samples collected within three months after transplantation from 14 subjects who never developed UTI in that time period. Among the 81 samples, 67 (83%) had a corresponding same day urine culture with the associated urine specimens that were assayed. The study additionally included 24 samples from 22 subjects who had a corresponding positive diagnosis of BK virus nephropathy by needle biopsy of the kidney allograft (BKVN positive group) and 10 samples from 10 subjects who had a normal protocol biopsy and was negative for BK virus (BKVN negative group). See also detailed clinical metadata in supplemental datatable "Clinical Data".
Urine supernatant isolation.
Approximately 50 mL of urine was centrifuged at 3,000 g and the supernatant was stored at -80 ˚C in 1 or 4 ml aliquots. Cell-free DNA was extracted from 1 ml (105 samples) or 4 ml (10 samples) of urine (Qiagen Circulating Nucleic Acid Kit, Qiagen, Valencia, CA).
Analysis of discordance against bacterial culture. In a single sample, urinary cfDNA did not identify the uropathogen reported by conventional culture (Raoultella). The subject had developed a prior Escherichia coli UTI by conventional bacterial culture on post op day 6, was treated with initially aztreonam but switched to cephalexin for 14 day course. The subject developed a Raoultella UTI by conventional bacterial culture on post op day 25 in which cfDNA analysis on the same day had high abundance of Escherichia coli UTI but no evidence of Raoultella infection. Given the discordant results, it is unclear if the second UTI is a recurrence as suggested by the cfDNA analysis or is a new infection as suggested by the urine culture data.
Negative control. To control for environmental and sample-to-sample contamination, a known-template control sample (IDT-DNA synthetic oligo mix, lengths 25, 40, 55, 70 bp, 0.20 µM eluted in TE buffer) was included in every sample batch and sequenced to approximately 25% of the depth of the cfDNA extracts (~5 million fragments). The five most abundant genera detected across the 23 microbiome controls consisted of Propionibacterium (22.9%), Salmonella (10.9%), Pseudomonas (7.7%), polyomavirus (5.4%), and E. coli (5.2%). The mean representation of each genus in the control was used to filter out genera in samples identified as possible contaminants. Possible sources of contamination in these experiments include: environmental contamination during sample collection in the clinic, nucleic acid contamination in reagents used for DNA isolation and library preparation, sample-to-sample contamination due to Illumina index switching 41 .
Library preparation and next generation sequencing. Sequencing libraries were prepared using a single-stranded library preparation optimized for the analysis of ultrashort fragment DNA, described previously 17 . Libraries were characterized using the AATI fragment analyzer. Due to the use of a custom read primer in place of Illumina read sequencing primer 1, digital PCR was not performed. Samples were pooled and sequenced on the Illumina NextSeq platform (paired-end, 2x75 bp). Approximately 50 million paired-end reads were generated per sample.
Analysis -Composition of the urinary microbiome.
Low quality bases and Illuminaspecific sequences are trimmed (Trimmomatic-0.32 42 ). Reads from short fragments were merged and a consensus sequence of the overlapping bases is determined using FLASH-1.2.7. Reads are aligned (Bowtie2, very sensitive mode 43 ) against the human reference (UCSC hg19). Unaligned reads are extracted, and the non-redundant human genome coverage is calculated (SAMtools 0.1.19 rmdup 44 ). To derive the urinary microbiome, reads are BLASTed (NCBI BLAST 2.2.28+) to a curated list of bacterial and viral reference genomes 45 . Short reads are assigned to specific taxa using a maximum likelihood algorithm that takes into account the ambiguity of read mapping 26 , as described in previous work 25, 46 . The relative abundance of higher level taxa are determined on the basis of the genomic abundance at the strain or species level.
Bacterial growth dynamics. We determined bacterial genome replication rates using the methods described by Brown et al. 29 . All bacterial strains within a sample were sorted and the GC-skew (the cumulative summation of GC content for sliding 10 bp windows across the genome) was used to identify the origin and terminus of replication (minimum and maximum GC-skew, respectively). We binned the genome by 1 kbp tiles, smoothed the coverage by running mean of 100 nearest neighboring tiles, determined the coverage in each tile and sorted the middle 90% of the tiles by coverage. We performed linear regression between the origin and terminus of replication after further removing the 5% least and most covered bins. The product of the slope of the regression line and the genome length was defined as the growth rate, a metric applied in previous analysis 29 . This analysis was applied for all bacterial strains with genome lengths greater than 0.5 Mbp, R 2 linear regression correlation greater than 0.90, and GINI index coefficient less than 0.2, for which at least 2500 BLAST hits were detected in the sample.
Nucleosome footprints in gene bodies. Paired-end reads are aligned using BWA (mem) to the hg19 human reference genome. Sequence read coverage around a list of TSS to the hg19 build, as described in similar work 19 , is determined based on BAM files using the SAMtools depth function. Nucleosomal protection at the TSS of specific genes is determined based on the loss of nucleosomal protection in a 2 kbp window centered on the TSS.
Proportion of donor-specific cfDNA in urine. The fraction of donor specific cfDNA in urine and plasma samples was estimated using approaches that modified from Refs. 14, 17, 25 to allow for donor estimates in the absence of donor genotype information. Sixty-three samples in the study were from sex-mismatched, donor-recipient pairs. Following adapter trimming and quality filtering, reads were aligned to the human genome build hg19. We processed human-aligned reads using HMMcopy 47 , binning the genome into windows of 500 bp to adjust for mappability and GC content. We further removed regions of the chrY that had high coverage in female-female donor-recipient pairs. We determined the donor fraction as follows:
Male donor: = 2 / ,
where Y and A are the coverage of the mappability-adjusted Y and autosomal chromosomes, respectively. SNP-genotyping information obtained from a recipient pretransplantation whole blood sample can be used to distinguish donor and recipient sequences for non-gender matched transplants. We compared the donor fraction estimated from the representation of sex chromosomes and autosomes to the donorfraction determined from SNP-genotyping for 16 samples available from a previous study and found a strong agreement for the two methods (Pearson's corr. of 0.973, p << 10 -6 ).
Mitochondrial donor fraction.
We determine the mitochondrial donor fraction using methods previously described 17 . We extracted genomic DNA from pre-transplant donor and recipient blood in parallel and amplified the mitochondrial DNA using the REPLI-g Mitochondrial DNA Kit (Qiagen). Amplified DNA was sheared to 300 bp and prepared and indexed using the NEBNext Ultra kit for Illumina (New England Biolabs, Ipswich, MA). We sequenced the consensus mitochondrial genomes on one lane of the Illumina MiSeq platform (2x150). Raw reads were trimmed and aligned to the human genome using BWA mem (hg19); average sequencing depth across the mitochondrial genome for sixteen samples (eight donor-recipient pairs) ranged from 50x-200x. Subsequent .bam files were analyzed for the nucleotide distribution at each base pair and the most frequent was chosen as the consensus nucleotide at that position. Post-transplant, cfDNA was also aligned to hg19 to determine mitochondrial-aligned cfDNA (mt-cfDNA) and we identified the frequency of each nucleotide at each base using bam-readcount (version 0.8.0). One sample was removed due to low depth of sequencing. We employed a two-tailed Student t-test under the alternative hypothesis that the mean mitochondrial donor fraction was greater than 50% to determine if the graft was the major contributor to mt-cfDNA in the urinary tract.
Clinical antimicrobial resistance determination. Antimicrobial susceptibility testing was performed on twenty-four matched samples from patients with clinically diagnosed UTIs at New York Presbyterian Hospital -Weill Cornell Medical Center. All tests considered in the analysis used minimal inhibitory concentration, except in one measurement of vancomycin resistance for one sample a bioMérieux Etest was performed, to assess the resistance of the cultured pathogenic microbe to up to twentyone antibiotics, though we only focus on vancomycin resistance.
Determining antimicrobial resistance gene presence. Nonhuman sequencing reads were aligned to a database of protein sequences of known antimicrobial resistance genes (CARD) using blastx. In many samples, the number of bacterial fragments were not deep enough to statistically identify SNP mutations. We, therefore restrict our identification only to resistance conferred via protein homolog, of which 2,158 genes were provided. We ran blastx such that we required the identity overlap to be 90% and the culling limit to be eight hits. The hits with the highest identity and overlap length were selected for each read and compared to the antimicrobial resistance classes using the CARD ontology. We confirmed the general utility of this approach using a short-read metagenomic sequence alignment software, Shortbred 48 . Briefly, the aforementioned reference genes from CARD were assembled into a proper reference using the shortbred_identify tool. Subsequently, this reference was aligned to our translated data using blastp (cutoff 85% identity). We confirmed the accuracy of this method by using a second, more stringent short-read metagenomic alignment tool, Shortbred 48 . For samples with many alignments to the CARD RGI reference database (>1000), the relative abundances of genes from the various antibiotic classes are strongly correlated between the two methods (mean Pearson correlation 0.851 for six samples).
Statistical analysis. All statistical analysis was performed using R 3.3.2. Unless otherwise noted, distribution comparison was performed using a Mann-Whitney U Test.
Data availability. The sequencing data that support the findings of this study will be made available in the database of Genotypes and Phenotypes (dbGaP).
